News

AstraZeneca announced positive results from the landmark Phase III DAPA-HF trial which showed that Farxiga (dapagliflozin) met the primary composite endpoint with a…
Read More...

The U.S. Food and Drug Administration approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia. “This new drug provides another option for the…
Read More...

iBio, Inc. announced that it has entered into a Master Services Agreement with Lung Biotechnology PBC, a subsidiary of United Therapeutics Corporation, to produce recombinant human…
Read More...

Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,…
Read More...

Juvenescence, a life sciences company utilising expert drug developers and artificial intelligence experts to create therapeutics and technologies to treat diseases of aging and to…
Read More...

Nabriva Therapeutics plc announced that the U.S. Food and Drug Administration (FDA) has approved Nabriva’s new drug applications for the oral and intravenous (IV) formulations of…
Read More...

Mateon Therapeutics and PointR Data announced that they have entered into a definitive agreement with respect to a merger, creating a publicly traded artificial intelligence (“AI”)…
Read More...

Sarepta Therapeutics announced it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) seeking…
Read More...

EAG Laboratories proudly announces the launch of a new laboratory in China dedicated to improving materials, products and electronics. Newly built in Shanghai, this facility brings the…
Read More...

Gilead Sciences, Inc. and Galapagos NV announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment…
Read More...

Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with ROS1-positive,…
Read More...

Harmony Biosciences, LLC (Harmony) announced that the U.S. Food and Drug Administration (FDA) approved WAKIX (pitolisant) for the treatment of excessive daytime sleepiness (EDS) in…
Read More...

GeneCentric Therapeutics, Inc. announced that it has acquired Select ImmunoGenomics, LLC, a Chapel Hill, NC-based provider of advanced immunogenomic, data analysis and biomarker…
Read More...

Phio Pharmaceuticals Corp. announced that is has entered into a research collaboration with the Helmholtz Zentrum München. The agreement covers the design and development of new targets…
Read More...

Syapse and the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) have signed a multi-year Research Collaboration Agreement (RCA) focused on the use of…
Read More...

The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant…
Read More...

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Calquence (acalabrutinib) as a monotherapy treatment for…
Read More...

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced positive results from the Phase III PAOLA-1 trial in women with…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission (EC) has approved variations to broaden the use of Imbruvica (ibrutinib) in two…
Read More...

Eli Lilly and Company announced Taltz (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety…
Read More...